Appendix A. Supplementary material

Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: a kinetic study

Cédric Thauvin[a], Jérôme Widmer[b], Inès Mottas[a,b], Sandra Hocevar[a], Eric Allémann[a], Carole Bourquin[a,b,c,*], Florence Delie[a,*]

[a]*School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Rue Michel-Servet 1, 1211 Geneva, Switzerland*

[b]*Chair of Pharmacology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 5, 1700 Fribourg, Switzerland*

[c]*Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland*

* Corresponding authors, the authors contributed equally to this work.

E-mail address: florence.delie@unige.ch (F. Delie) and carole.bourquin@unige.ch (C. Bourquin)

PLA


300
250
200
150
100
50
0
556.00
1852.42
8
7
6
5
4
3
2
1
f1 (ppm)

PLA-C8


200
150
100
50
0
556.00
1795.26
16.58
2.22
8
7
6
5
4
3
2
1
f1 (ppm)

PLA-C20



PLA-mPEG2000



Fig. S1. ^{1}H NMR spectra of PLA-based polymers.



Fig. S2. R848-loaded PLA-NP activation of TNF-α release in macrophages. The release of TNF-α from J774 cells was assessed after incubation for 24 h with R848-loaded NP (R848 concentration: 0.1 µg/ml for free R848 and all R848-loaded NP conditions). Each bar represents mean ± SD, n=3. Data show one representative experiment out of three.